

17th March, 2026

To, Corporate Relations Department Bombay Stock Exchange Ltd (BSE) Phiroze Jheejheebhoy Towers, Dalal Street, Mumbai - 400 001. Scrip Code - 543308 ISIN: INE967H01025	To, The Listing Department National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Bandra - Kurla Complex Mumbai - 400 051. Symbol - KIMS ISIN: INE967H01025
--	--

Dear Sir/ Madam,

Sub: Newspaper Advertisement- Notice of Postal Ballot.

Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed a copy of newspaper publication of the Postal Ballot Notice published in Financial Express (English) and Navatelangana (Telugu) with regard to e-Voting information and completion of dispatch of Notice, in terms of Section 108 of the Companies Act, 2013 read with Rule 20 of Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The said publication may also be accessed on the website of the Company i.e <https://www.kimshospitals.com/investors/> under Regulation 46 of SEBI (LODR) Regulations, 2015/ Newspaper advertisements.

This is for your information and records

Thanking you,

Yours truly

For Krishna Institute of Medical Sciences Limited

Nagajayanthi J. R
Company Secretary & Compliance Officer

Encl: As above

GENERIC VERSIONS EXPECTED TO BE AT LEAST 50% CHEAPER

Ozempic patent expiry heralds weight-loss drug boom in India

SATVIKI SANJAY
March 16

CHEAPER OPTIONS

SWATI PRADHAN SEES about 12 obesity patients a day at her small clinic in southern Mumbai. She expects this number to at least double from this month as Indian drug makers prepare to launch off-patent versions of Novo Nordisk's blockbuster weight-loss drug at half the price.

The Danish drugmaker's key patent on semaglutide, the active ingredient in Ozempic and Wegovy that reshaped the global weight-loss industry, expires in India on March 20. At least five Indian drugmakers — Mankind Pharma, Ajanta Pharma, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, and Lupin — are gearing up to sell cheaper copies of the drug immediately after the expiry, according to their statements and post-earnings calls.

This has prompted hospitals, telehealth firms and clinics across India to expand obesity-focused services in anticipation of a demand surge. The generic versions are expected to be at least 50% cheaper — priced at around ₹5,000 (\$54) for a weekly dose — than Novo's therapy, according to people familiar with the matter who spoke on the condition of anonymity as pricing information is competitive.

India is the first major country after Canada where Novo is losing patent on semaglutide and will see an onslaught of generic versions. With its large disease burden and an entrenched pharmaceutical industry known for copycat drugs, India is set to be the test case for how much the prices of these anti-obesity drugs can plummet.

Metabolic disorders such as thyroid disease, diabetes and fatty liver have surged among India's 1.4-billion-plus population, largely due to increas-

India is the first major country after Canada where Novo is losing patent on semaglutide

Metabolic disorders have surged among India's 1.4-bn-plus population

India's potential GLP-1 market size is likely to expand from ₹1,000 crore last year to as much as ₹5,000 crore by 2030

Prices could decline by 40% to 50% after the patent expires and then as more drugmakers enter the segment



ingly sedentary urban lifestyles. On the other hand, high-calorie diets, dripping with oil and fat, have contributed to rising weight gain in the country, which has the world's third-largest overweight population, trailing the US and China.

In a move aimed at curbing aggressive commercial practices as demand booms, India's drug regulator has banned advertising and promotional activity related to weight-loss programmes. The prohibition also extends to disease-awareness campaigns, social media endorsements and corporate marketing initiatives.

Pradhan, who's a doctor specialising in obesity consultation, runs LiveLight Clinic that charges between ₹21,000 and ₹26,000 a month. The programme includes services ranging from dietary counseling and blood tests, to side-effect management and weekly check-ins.

The programme ensures

weight loss of as much as 5 kg a month, which is sometimes not possible if patients take injections without professional support, said Pradhan.

Those who opt out of the programme at an initial stage "start seeing side effects or their weight loss slows down, and end up contacting the clinic," she added.

Obesity clinics

Hospital chains Apollo Health & Lifestyle and Fortis Health-care are either launching or expanding obesity management clinics staffed by physicians, dietitians, fitness trainers and psychologists. Novo has already partnered with Apollo Clinics to set up dedicated obesity centres.

The hospital chain continues to evaluate the weight management space given the large opportunity here, Krishnan Akhileswaran, Apollo Hospitals Enterprise's chief financial offi-

cer, told Bloomberg News.

Diagnostic chains like Tata IMG Technologies are rolling out discounted weight check-up packages. Pharmacies including PharmEasy offer home delivery of these drugs after e-consultations, though market researcher Pharmarack says online channels remain a small share of overall sales.

Bengaluru-based Cipun Mishra shelled out ₹65,000 in May for a three-month consultancy with an app-based wellness platform HealthifyMe Wellness. The package he bought included a wide array of services from a monthly consultation with an endocrinologist, to round-the-clock access to fitness and diet coaches as well as weight-loss vials and a monthly guided injection, he said.

Cipla-Lilly pact

Cipla, which markets Eli Lilly's tirzepatide drug as Yurpeak in India, is working with clinics in smaller towns. Lilly's drug is still under patent protection.

Health professionals are "very keen on how to prescribe, how to manage" the category, for which drugmakers like Cipla can work alongside them, said Cipla's Chief Executive Officer Designate Achin Gupta.

Consultants see significant revenue potential for providers that bundle drugs with diagnostics and follow-up care

Market expansion driven by patients starting generic therapy would directly benefit health care institutions, Ganguli said. **BLOOMBERG**

One Battle After Another sweeps Oscars with 6 awards



Bollywood legend Dharmendra was conspicuously absent from the 'In Memoriam' segment

Actor Priyanka Chopra Jonas made a stylish return to the Academy Awards stage, presenting an award at the 98th Oscars ceremony held at the Dolby Theatre

PAUL THOMAS ANDERSON'S *One Battle After Another* was crowned best picture at the 98th Academy Awards, handing Hollywood's top honour to a comic, multi-generational American saga of political resistance.


The film won a total of six Oscars.

The ceremony saw Michael B Jordan win best actor and *Sinners* cinematographer Autumn Durald Arkapaw make Oscar history as the first female director of photography to win the award.



Best Actress
Jessie Buckley (*Hamnet*)

Best Actor
Michael B Jordan (*Sinners*)



Best Picture
One Battle After Another

Best Supporting Actress
Amy Madigan (*Weapons*)

Best Supporting Actor
Sean Penn (*One Battle After Another*)

Best Director
Paul Thomas Anderson (*One Battle After Another*)

Best Original Song
Golden from *KPop Demon Hunters*, EJAE, Mark Sonnenblick, Joong Gyu Kwak, Yu Han Lee, Hee Dong Nam, Jeong Hoon Seon and Teddy Park

Best Original Score
Ludwig Goransson (*Sinners*)

Best Animated Film
KPop Demon Hunters

Best International Film
Sentimental Value

Ehrlich, author of *The Population Bomb*, dies

KEITH SCHNEIDER
March 16



Paul R Ehrlich was 93

PAUL R EHRLICH, an eminent ecologist and population scientist whose best-selling book, "The Population Bomb," was celebrated as a prescient warning of a coming age of food shortages and famine but later criticised by conservatives and academic rivals for what they called its sky-is-falling rhetoric, died on Friday in Palo Alto, California. He was 93.

His death, at a nursing facility in the retirement community where he lived, was caused by complications of cancer, his daughter, Lisa Marie Daniel, said.

lectures into an article published in December 1967 in *New Scientist* magazine.

Six months later, encouraged by David Brower, the executive director of the environmental group the Sierra Club, to write a book on the subject, Ehrlich published "The Population Bomb." In 233 pages, he asserted that the planet's condition began to deteriorate rapidly in the 1950s, when the rate of population growth exceeded the increase in food production — or, as he put it, when "the stork passed the plow." He called on couples to limit their families to one or two children.

Witty, knowledgeable and

not at all reticent, Ehrlich gained a huge audience on television, especially on "The Tonight Show Starring Johnny Carson," which he appeared on roughly 20 times. His forecast of food riots in the United States and of imminent global famines caused by escalating population growth found a worldwide readership.

One of the best-selling non-fiction books about the environment to date, "The Population Bomb" sold three million copies and transformed Dr. Ehrlich, who was 37 at the time, into one of the global environmental movement's most recognised leaders.

Krishna Institute of Medical Sciences Limited
Registered Office: 1-8-31/1, Minister Road, Secunderabad - 500 003, Telangana, India. Phone: +91 40 4488 5000 / 4488 5184 | Fax: +91-40-27840980
www.kimshospitals.com
CIN: L55101TG1973PLC040558



NOTICE OF POSTAL BALLOT / E-VOTING

NOTICE is hereby given to the shareholders of Krishna Institute of Medical Sciences Limited (the "Company") pursuant to the provisions of Section 110 read with section 108 and all other applicable provisions of the Companies Act, 2013 read with the Companies (Management and Administration) Rules, 2014 (collectively the "Act") read with General Circular Nos.14/2020 dated 8th April 2020, 17/2020 dated 13th April 2020, 22/2020 dated 15th June 2020, 33/2020 dated 28th September 2020, 39/2020 dated 31st December 2020, 10/2021 dated 23rd June 2021, 20/2021 dated 8th December 2021, 03/2022 dated 5th May 2022, 11/2022 dated 28th December 2022, 09/2023 dated 25th September 2023, 09/2024 dated 19th September 2024, 03/2025 dated September 22, 2025 and/or any other circulars issued from time to time by the Ministry of Corporate Affairs, Government of India (the "MCA Circulars"), Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India ("SS-2"), Regulation 44 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations") and other applicable laws, rules and regulations (including any statutory modification(s) or reenactment(s) thereof, for the time being in force), read with the equity listing agreement executed with the stock exchanges on which the equity shares of the Company are listed, the Company has completed the dispatch of the Postal Ballot notice through e-mail to all its shareholders, who have registered their e-mail IDs on 13th March, 2026 (Cut-off date) seeking consent of the members through voting by electronic means to transact the business as set out in the Postal Ballot Notice dated 11th March, 2026:

Sr. No	Description of Resolution	Type of Resolution
1.	Issuance of equity shares to investors by way of a qualified institutions placement for raising of funds	Special

In pursuance of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 and Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the aforesaid MCA Circulars, the Company has engaged the services of Link Intime India Private Limited ("LIPL") to provide e-voting facility to the members of the Company through Instavote platform at the link <https://instavote.linkintime.co.in> for passing of the Special Resolution mentioned in the Postal Ballot Notice.

The postal ballot notice has been sent only through electronic mode to those members who have registered their e-mail addresses with the Company or with the Depositories. In compliance with the requirements of the MCA Circulars, the hard copy of the postal ballot notice along with postal ballot forms and pre-paid business envelope will not be sent to the shareholders for this postal ballot and the shareholders are requested to communicate their assent or dissent through the remote e-voting system only.

Therefore, those shareholders who have not yet registered their e-mail addresses are requested to get their e-mail addresses submitted by following the procedure as mentioned in the said postal ballot notice.

Members whose names are recorded in the Register of Members of the Company or in the Register of Beneficial Owners maintained

by the Depositories as of the cut-off date i.e. Friday, 13th March 2026 will be entitled to cast their votes by e-voting. The persons who are not members of the Company as of the cut-off date, however, have received the notice, should treat this notice as informative only.

Members are requested to carefully read the instructions for voting through e-voting as provided in the postal ballot notice. Members are also requested to note the following:

S.No	Particulars	Date	Time
1	The cut-off date for determining the members eligible for e-voting/postal ballot	13.03.2026	-
2	Date of dispatch of the postal ballot notice through e-mail	16.03.2026	-
3	Date and time of commencement of remote e-voting/postal ballot	17.03.2026	9:00 A.M.
4	Date and time of the closure of remote e-voting/postal ballot (Remote e-voting facility will be disabled beyond this date and time)	15.04.2026	5:00 P.M.

Mr. Krishna Rao Inturi, Proprietor of M/s. IKR & Associates, Practicing Company Secretaries, Hyderabad Telangana has been appointed as the scrutinizer for conducting the Postal Ballot voting process in a fair and transparent manner and for the purpose of ascertaining the majority. The results of the postal ballot e-voting shall be announced by the Chairman & Managing Director of the Company or any other person authorized by him within two working days from the closure of the e-voting platform and the same shall be intimated to BSE Limited (BSE) and National Stock Exchange (NSE), the stock exchanges where the equity shares of the Company are listed. The voting results shall also be displayed on the Company's website www.kimshospitals.com and on the LIPL's website <https://instavote.linkintime.co.in>.

For any grievance/ queries relating to voting by electronic means, the shareholders are requested to write an e-mail at enotices@linkintime.co.in or call at Tel:+91 22 4918 6000 or contact M/s. Link Intime India Private Limited, "Surya", 35, Mayflower Avenue, Behind Senthil Nagar, Sowipalayam Road, Coimbatore - 641028 or their telephone number +91 422 2314792 or Ms. Nagajayanthi J.R, Company Secretary and Compliance Officer at the Company's Registered Office at D. No. 1-8-31/1, Minister Road, Secunderabad - 500003; or Phone No: +91 40 4488 5000 / 4488 5184; or E-mail ID: cs@kimshospitals.com.

The Notice of the Postal Ballot is available on the Company's website www.kimshospitals.com, LIPL's website <https://instavote.linkintime.co.in>, on the website of the BSE Limited www.bseindia.com and National Stock Exchange Limited (NSE) <https://www.nseindia.com/>

By order of the Board
For Krishna Institute of Medical Sciences Limited
Sd/-
Nagajayanthi J.R
Company Secretary and Compliance officer

Place: Hyderabad
Date: 16.03.2026

WAR IN THE MIDDLE EAST

Where is it headed, and what happens now

- What is the endgame?
- Is US & Israel justified in attacking Iran?
- What is happening inside Iran?
- What will be new Supreme Leader Mojtaba Khomeini's strategy?
- How does west Asia view the war?
- How is India's position on the war perceived by different nations?
- How far is it going to impact India's economy and its diaspora in the region?

19 March 2026 | **05:30 PM** | Join us on **ZOOM**

Scan to Register

Navdeep Suri
Former Indian Ambassador to UAE & Egypt
In conversation with

Shubhajt Roy
Diplomatic Editor
The Indian Express

The Indian EXPRESS
— JOURNALISM OF COURAGE —